Alexion Pharma Q4 top line up 17%; EPS down 62%; shares down 5% premarket

|About: Alexion Pharmaceutical... (ALXN)|By:, SA News Editor

Alexion Pharmaceuticals (NASDAQ:ALXN) Q4 results ($M): Total Revenues: 700.9 (+16.9%); Net Product Sales: 700.4 (+16.8%); Soliris Sales: 688.5 (+14.8%); Kanuma Sales: 336.

Net Income: 66.6 (-56.6); EPS: 0.29 (-61.8%).

2016 Guidance: Total Revenues: $3.05B - 3.1B; Soliris: $2.900B - 2.925B; Metabolic Franchise: $150M - 175M; EPS: $5.00 - 5.20.

Shares are down 5% premarket on light volume. Revenues were slightly short of consensus.

Previously: Alexion Pharmaceuticals beats by $0.03, misses on revenue (Feb. 3)

Subscribe for full text news in your inbox